Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 29, 2016updated 22 Nov 2018 11:20am

SRS Medical secures CE mark for spanner temporary prostatic stent

US-based medical device company SRS Medical Systems has secured the CE mark approval for its spanner temporary prostatic stent (STPS) in the European Economic Area (EEA).

Spanner

US-based medical device company SRS Medical Systems has secured the CE mark approval for its spanner temporary prostatic stent (STPS) in the European Economic Area (EEA).

The spanner acts as an alternative to indwelling (Foley) and intermittent urinary catheters for male patients with bladder outlet obstruction (BOO).

The internally placed device allows the patient to relieve their bladders without being conscious of the device presence.

SRS Medical CEO Lee Brody said: "The Spanner is proven to have significant impact on medical outcomes, and often has a transformational impact on patient quality of life.

"We are excited to receive this approval, and we look forward to working with our European partners to deliver The Spanner to the patients that will benefit from it the most."

The US Food and Drug Administration (FDA) approved STPS is a Class III medical device designed to maintain urine flow and enable voluntary urination in male patients with lower urinary tract symptoms (LUTS).

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The device features two anchors and a silicone tube which minimises resistance in the bladder neck and prostatic urethra without stenting the external sphincter.

"The Spanner is proven to have significant impact on medical outcomes, and often has a transformational impact on patient quality of life."

The application of the spanner does not require anesthesia.

The spanner, apart from treating BOO, also reduces infection risk and medical complication in patients who will be subjected to benign prostatic hyperplasia (BPH) treatment.

It has the ability to predict a potential BPH treatment outcome in the patients.

The spanner results long-term relief for patients who are unfit to undergo prostate procedures.


Image: SRS Medical’s Spanner Temporary Prostatic Stent. Photo: courtesy of Business Wire.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU